PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.
Analyze analyst forecasts for the company and compare them with competitors.
42.52K
Worse than SGMO's estimated revenue of 59.13M.
-8.50K
Better than SGMO's estimated ebitda of -53.03M.
-1.41
Worse than SGMO's estimated eps of -0.47.
-41.31M
Better than SGMO's estimated net income of -81.77M.
-8.50K
Better than SGMO's estimated ebit of -54.66M.
1.58M
Better than SGMO's estimated sg&a expense of 31.35M.
Analyze DCF forecasts for the company and compare them with competitors.
1.03M
Worse than SGMO's revenue of 111.30M.
-9.97%
Worse than SGMO's revenue growth rate of 0.54%.
-33.41M
Better than SGMO's ebitda of -189.17M.
-3243.20%
Worse than SGMO's ebitda margin of -169.97%.
-34.10M
Better than SGMO's ebit of -201.28M.
-3311.07%
Worse than SGMO's ebit margin of -180.85%.
699.00K
Better than SGMO's depreciation of 12.11M.
108.91M
Worse than SGMO's total cash of 277.63M.
10573.79%
Better than SGMO's cash as percentage of revenue of 249.45%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
10.13M
Better than SGMO's accounts payable of 22.42M.
983.50%
Worse than SGMO's payables as percentage of revenue of 20.14%.
-366.00K
Worse than SGMO's capital expenditure of -20.17M.
-35.53%
Better than SGMO's capex as percentage of revenue of -18.12%.
4.99%
Better than SGMO's weighted average cost of capital (wacc) of 9.14%.
5.02%
Better than SGMO's cost of equity of 9.58%.
4.08%
Better than SGMO's cost of debt of 4.40%.
-0.23
Better than SGMO's beta of 1.10.
30.07M
Better than SGMO's diluted shares outstanding of 174.44M.
1.57M
Better than SGMO's total debt of 38.10M.
49.31M
Worse than SGMO's total equity of 409.94M.
50.89M
Worse than SGMO's total capital of 448.05M.
3.09%
Better than SGMO's debt weighting of 8.50%.
96.91%
Better than SGMO's equity weighting of 91.50%.
-32.98M
Better than SGMO's ebiat of -201.73M.
-28.05M
Better than SGMO's unlevered free cash flow of -283.41M.
2.00%
Equal to SGMO's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than SGMO's net debt of -7.10M.
71.33M
Better than SGMO's equity value of -4.28B.
2.37
Better than SGMO's equity value per share of -24.51.